Wonglita Tablet contains Pioglitazone 15 mg, an oral antihyperglycemic agent belonging to the thiazolidinedione class, indicated for the management of type 2 diabetes mellitus. Pioglitazone improves glycemic control by enhancing peripheral insulin sensitivity, primarily in adipose tissue, skeletal muscle, and the liver, thereby reducing insulin resistance. This results in increased glucose uptake and decreased hepatic glucose output. Wonglita is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas when diet and exercise alone are insufficient to achieve adequate glycemic control. The tablet should be taken once daily, with or without food, as directed by a healthcare professional. Common adverse effects include weight gain, edema, and an increased risk of heart failure in susceptible individuals; therefore, caution is advised in patients with pre-existing cardiac conditions. Liver function tests should be monitored periodically due to rare reports of hepatotoxicity. Wonglita is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, and those with known hypersensitivity to pioglitazone. It is essential to use this medication under strict medical supervision to optimize therapeutic outcomes and minimize potential risks.